Does 1 + Beat 2 +? And ADC-After-ADC

Category - HER2+

HER2+ Breast Cancer: The Most Transformed Disease in Oncology?

Eliminating the Surprise: Mapping the Path for Adjuvant Therapy After Surgery

Is pCR Enough? Why Regulators Still Want EFS Data

“Best Drug on Earth” Isn’t Enough If Patients Can’t Tolerate It

Does Higher pCR Come at a Cost? Weighing Efficacy vs Toxicity in DB-11

Beyond KATHERINE: The DB-05 Shift in High-Risk HER2+ Disease

The New 1st Line Reality in HER2+ mBC: Why the Strongest Tool Goes First

PATINA, HER2CLIMB-05 & the Maintenance Therapy Debate

Vigilance is Key: Managing ILD with T-DXd

The 1st Line Decision: Why T-DXd is Redefining the Start

Beyond CLEOPATRA: When the 1L Standard Falls Short

Cleopatra’s Survival Impact in HER2+ Metastatic Breast Cancer